Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Free Report) – Investment analysts at Erste Group Bank cut their FY2026 EPS estimates for shares of Sandoz Group in a research report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will earn $4.17 per share for the year, down from their prior estimate of $4.22. Erste Group Bank currently has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.15 per share.
Sandoz Group Trading Down 0.3%
Sandoz Group stock opened at $99.36 on Wednesday. The firm has a 50 day simple moving average of $87.28 and a 200 day simple moving average of $83.75. Sandoz Group has a 1-year low of $62.26 and a 1-year high of $100.34.
About Sandoz Group
Sandoz Group AG is a Switzerland-based pharmaceutical company focused on generic and biosimilar medicines. Its portfolio includes prescription medicines across therapeutic areas such as anti-infectives, immunology, oncology, ophthalmology, respiratory care and cardiovascular treatments. The company also supplies complex generics, including injectable, inhaled and other specialty formulations.
Sandoz serves patients and healthcare providers through a broad international commercial and manufacturing network, with operations and products spanning Europe, North America, Asia and other global markets.
Featured Stories
- Five stocks we like better than Sandoz Group
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
